NEWRON PHARMACEUT. EO-20 (NP5) - Cash Flow Conversion Efficiency

Latest as of June 2025: 21.242x

Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has a cash flow conversion efficiency ratio of 21.242x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€33.60 Million ≈ $39.29 Million USD) by net assets (€1.58 Million ≈ $1.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

NEWRON PHARMACEUT. EO-20 - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how NEWRON PHARMACEUT. EO-20's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of NEWRON PHARMACEUT. EO-20 for a breakdown of total debt and financial obligations.

NEWRON PHARMACEUT. EO-20 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Hainan Yedao Group Co Ltd SHG:600238	-0.076x
Lanner Electronics TWO:6245	-0.006x
First Bank NASDAQ:FRBA	0.039x
EQT Holdings Ltd AU:EQT	0.045x
Guangdong Tianhe Agricultural Means SHE:002999	-0.238x
Mandalay Resources Corp TO:MND	0.109x
Shenzhen Sine Electric Co. Ltd. A SHG:688395	0.031x
Jiangsu Gaoke Petrochemical Co SHE:002778	0.118x

Annual Cash Flow Conversion Efficiency for NEWRON PHARMACEUT. EO-20 (2005–2024)

The table below shows the annual cash flow conversion efficiency of NEWRON PHARMACEUT. EO-20 from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see NEWRON PHARMACEUT. EO-20 market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€1.46 Million ≈ $1.70 Million	€-17.61 Million ≈ $-20.59 Million	-12.081x	-3663.28%
2023-12-31	€-29.91 Million ≈ $-34.97 Million	€-10.14 Million ≈ $-11.85 Million	0.339x	-57.12%
2022-12-31	€-14.03 Million ≈ $-16.40 Million	€-11.09 Million ≈ $-12.97 Million	0.791x	+121.46%
2021-12-31	€3.11 Million ≈ $3.63 Million	€-11.45 Million ≈ $-13.38 Million	-3.684x	-307.54%
2020-12-31	€17.25 Million ≈ $20.16 Million	€-15.59 Million ≈ $-18.22 Million	-0.904x	-51.35%
2019-12-31	€36.80 Million ≈ $43.02 Million	€-21.98 Million ≈ $-25.69 Million	-0.597x	-105.27%
2018-12-31	€54.84 Million ≈ $64.11 Million	€-15.95 Million ≈ $-18.65 Million	-0.291x	-134.45%
2017-12-31	€67.72 Million ≈ $79.17 Million	€-8.40 Million ≈ $-9.83 Million	-0.124x	+68.48%
2016-12-31	€49.75 Million ≈ $58.16 Million	€-19.58 Million ≈ $-22.89 Million	-0.394x	-13.58%
2015-12-31	€37.11 Million ≈ $43.39 Million	€-12.86 Million ≈ $-15.04 Million	-0.347x	-1.43%
2014-12-31	€29.26 Million ≈ $34.21 Million	€-10.00 Million ≈ $-11.69 Million	-0.342x	+32.56%
2013-12-31	€21.09 Million ≈ $24.66 Million	€-10.69 Million ≈ $-12.49 Million	-0.507x	-340.15%
2012-12-31	€27.61 Million ≈ $32.28 Million	€5.83 Million ≈ $6.81 Million	0.211x	+128.11%
2011-12-31	€6.58 Million ≈ $7.70 Million	€-4.94 Million ≈ $-5.78 Million	-0.750x	+52.17%
2010-12-31	€12.19 Million ≈ $14.25 Million	€-19.13 Million ≈ $-22.36 Million	-1.569x	-99.27%
2009-12-31	€29.28 Million ≈ $34.23 Million	€-23.06 Million ≈ $-26.95 Million	-0.787x	-80.96%
2008-12-31	€45.81 Million ≈ $53.56 Million	€-19.93 Million ≈ $-23.30 Million	-0.435x	-80.11%
2007-12-31	€57.40 Million ≈ $67.11 Million	€-13.87 Million ≈ $-16.21 Million	-0.242x	-70.22%
2006-12-31	€67.86 Million ≈ $79.33 Million	€-9.63 Million ≈ $-11.26 Million	-0.142x	+83.14%
2005-12-31	€17.02 Million ≈ $19.90 Million	€-14.33 Million ≈ $-16.75 Million	-0.842x	--

About NEWRON PHARMACEUT. EO-20

XETRA:NP5 Germany Biotechnology

Market Cap

$369.88 Million

€316.38 Million EUR

Market Cap Rank

#14068 Global

#1415 in Germany

Share Price

€15.85

Change (1 day)

-0.63%

52-Week Range

€7.16 - €32.55

All Time High

€32.55